These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 750535

  • 1. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C, Rachmilewitz EA.
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
    Hershko C, Rachmilewitz EA.
    Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354
    [No Abstract] [Full Text] [Related]

  • 3. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Evaluation of iron overload in thalassemia].
    Piga A, Davico S, Magliano M, Luzzatto L, Sandri A, Gabutti V.
    Pediatr Med Chir; 1986 Jun; 8(1):9-13. PubMed ID: 3725619
    [Abstract] [Full Text] [Related]

  • 7. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C, De Stefano P, Bongo IG, Avato F, Cazzola M.
    Am J Pediatr Hematol Oncol; 1984 Jun; 6(3):340-3. PubMed ID: 6517228
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S, Cossu P, Sanna G, Frau F, Loi E, Lobrano R, Nucaro A, Toccafondi C, Cornacchia G, Loi A, Cao A.
    Acta Haematol; 1982 Jun; 67(1):49-56. PubMed ID: 6800202
    [Abstract] [Full Text] [Related]

  • 10. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 11. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Sep; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I, Hatzidimitriou-Papazacharia K, Spiliotopoulou J, Tsagarakis N, Digenopoulou E.
    Birth Defects Orig Artic Ser; 1988 Sep; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract] [Full Text] [Related]

  • 19. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
    Kattamis C, Lagos P, Langona E.
    Prog Clin Biol Res; 1979 Sep; 34():351-9. PubMed ID: 531060
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.